PWA
NBIX icon

Provenance Wealth Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Provenance Wealth Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12
Closed -$1.33K – 505
2025
Q1 		$1.33K Hold
12
– – ﹤0.01% 442
2024
Q4 		$1.64K Hold
12
– – ﹤0.01% 442
2024
Q3 		$1.38K Hold
12
– – ﹤0.01% 503
2024
Q2 		$1.65K Hold
12
– – ﹤0.01% 392
2024
Q1 		$1.66K Hold
12
– – ﹤0.01% 428
2023
Q4 		$1.58K Hold
12
– – ﹤0.01% 485
2023
Q3 		$1.35K Buy
+12
New +$1.26K ﹤0.01% 364

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Provenance Wealth Advisors's NBIX Position: Q2 2025 in Review

Provenance Wealth Advisors sold out of Neurocrine Biosciences (NBIX) in Q2 2025, closing a stake of 12 shares — an estimated $1.33K sold.

Provenance Wealth Advisors first reported a position in NBIX in Q3 2023 and held it in 7 quarters. The position peaked at $1.66K in Q1 2024. 585 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.

  • Provenance Wealth Advisors reported no remaining Neurocrine Biosciences position as of Q2 2025 after selling out during the quarter.
  • Provenance Wealth Advisors sold 12 Neurocrine Biosciences shares in Q2 2025, an estimated $1.33K.
  • Provenance Wealth Advisors first reported a position in Neurocrine Biosciences in Q3 2023 and held it in 7 quarters.
  • Provenance Wealth Advisors's Neurocrine Biosciences position peaked at $1.66K in Q1 2024.
  • 585 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.

Based on Provenance Wealth Advisors's 13F filing for Q2 2025, filed 15 Aug 2025.